Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

Phase 2b SunRISe-1 data showed TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive, high-risk ...

The key takeaways are that prostate cancer misinformation is widespread across online platforms and spans many different ...

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor ...

An expert discusses how the diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) require careful recognition of characteristic dermatologic and hematologic features, with ...